Reducing Door-to-Balloon Times With Medical Simulation

Medical simulation is well suited to educate care teams in reducing door-to-balloon times.

By Mark A. Turco, MD, FSCAI, FACC, and Amy L. Ketron, RN, BSN

Xience V (Promus) Drug-Eluting Coronary Stent

Design features, preclinical data, and clinical outcomes.

By Krishna Sudhir, MD, PhD, FRACP, FACC; David R. Rutledge, Pharm D, FAHA, FCCP; Alena Pechonkina, MD; and Chuck Simonton, MD, FACC, FSCAI

Taxus Clinical Update

Experts discuss the current role of the Taxus stent.

By Mark A. Turco, MD, FSCAI, FACC, and Eberhard Grube, MD, FSCAI, FACC

Sirolimus-Eluting Cypher Stent

A standard of comparison for drug-eluting stents.

By Colin M. Barker, MD, and David E. Kandzari, MD

Clinical Trial Update on the Endeavor Stent

An overview of the completed and ongoing clinical trial program of the Endeavor zotarolimus-eluting stent platform.

By Ajay J. Kirtane, MD, SM; Marcos Valerio, BS; and Martin B. Leon, MD

Stent Thrombosis in BMS and DES

More issues than answers.

By Mitchell W. Krucoff, MD, FACC

Stent Pipeline

An update on absorbable polymers and stents.

By Alexandre Abizaid, MD, PhD; Andre Lima Brito, MD; and J. Ribamar Costa Jr, MD

2008 FDA Guidelines for DES

The how and why of FDA oversight of drug-eluting stents.

By Andrew Farb, MD, and Ashley B. Boam, MS

An Interview With Jeffrey W. Moses, MD

One of cardiology's preeminent experts shares his views on the state of the field, the current and future role of DES, and what we can look forward to from TCT 2008.

By Jeffrey W. Moses, MD

2008 Drug-Eluting Stent Update

By Ted E. Feldman, MD, FSCAI, Chief Medical Editor